Nicholas Investment Partners LP cut its holdings in Incyte Corporation (NASDAQ:INCY) by 4.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 84,640 shares of the biopharmaceutical company’s stock after selling 4,210 shares during the period. Incyte comprises approximately 0.7% of Nicholas Investment Partners LP’s investment portfolio, making the stock its 22nd biggest holding. Nicholas Investment Partners LP’s holdings in Incyte were worth $9,881,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of INCY. Tower Research Capital LLC TRC raised its holdings in shares of Incyte by 13.8% in the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 108 shares during the last quarter. Seven Eight Capital LP acquired a new stake in shares of Incyte in the second quarter valued at approximately $129,000. IFP Advisors Inc increased its holdings in Incyte by 9.9% during the second quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 103 shares during the last quarter. Sun Life Financial INC increased its holdings in Incyte by 9,069.2% during the second quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 1,179 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in Incyte by 130.4% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,325 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 750 shares during the last quarter. Institutional investors own 90.86% of the company’s stock.
In related news, President Herve Hoppenot sold 70,502 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $119.45, for a total value of $8,421,463.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Paul A. Friedman sold 28,507 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The disclosure for this sale can be found here. Insiders have sold a total of 106,638 shares of company stock valued at $12,339,027 in the last three months. Insiders own 17.70% of the company’s stock.
Incyte Corporation (NASDAQ:INCY) opened at $97.94 on Monday. Incyte Corporation has a 52 week low of $94.78 and a 52 week high of $153.15. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.11. The business had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The company’s revenue for the quarter was up 41.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 EPS. analysts anticipate that Incyte Corporation will post -1.33 EPS for the current fiscal year.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
What are top analysts saying about Incyte Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Incyte Corporation and related companies.